Biotechnology The USA’s Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease, including crizanlizumab (Adakveo, from Novartis), voxelotor (Oxbryta, from Global Blood Therapeutics), and L-glutamine (Endari, from Emmaus Life Sciences). 24 January 2020